Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02709655
Other study ID # 12709A
Secondary ID 2008-005353-38
Status Completed
Phase Phase 3
First received
Last updated
Start date May 18, 2016
Est. completion date January 21, 2022

Study information

Verified date August 2022
Source H. Lundbeck A/S
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Investigation of the efficacy and safety of a new potential treatment of Major depressive disorder (MDD) in paediatric participants (age 7 to 11 years).


Recruitment information / eligibility

Status Completed
Enrollment 683
Est. completion date January 21, 2022
Est. primary completion date January 21, 2022
Accepts healthy volunteers No
Gender All
Age group 7 Years to 11 Years
Eligibility Inclusion Criteria: 1. The participant has MDD, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5™). 2. The participant has a CDRS-R total score =45 at the Screening Visit and the Baseline. 3. The participant has a CGI-S score =4 at the Screening Visit and the Baseline. 4. The participant is a boy or girl, aged =7 and <12 years at Screening Visit 5. The participant has provided assent to participation and parent(s)/legal representative (s) signed the Informed Consent Form. Exclusion Criteria: 1. The participant has participated in a clinical study <30 days prior to the Screening Visit. 2. The participant has previously participated in a study with vortioxetine. Other protocol defined inclusion and exclusion criteria may apply

Study Design


Intervention

Drug:
Vortioxetine 10 mg/day
10 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
Vortioxetine 20 mg/day
20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
Fluoxetine 20mg/day
20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
Other:
Placebo
Encapsulated tablet, orally

Locations

Country Name City State
Bulgaria MHAT Targovishte AD Targovisthe
Bulgaria Diagnostic Consultative Center Mladost-M Varna OOD Varna
Canada Paediatric Sleep Research Inc. Toronto Ontario
Colombia Centro de Investigaciones y Proyectos en Neurociencias CIPNA LTDA IPS. Barranquilla Atlantico
Colombia E.S.E. Hospital Mental de Antioquia HOMO Bello Antioquia
Colombia Centro de investigaciones del Sistema Nervioso SAS Grupo CISNE SAS Bogota DC
Colombia Psynapsis Salud Mental S.A. Pereira Risaralda
Estonia Marienthali Kliinik Tallinn
France Cabinet Psyche Douai Nord
France Centre Medical Ambroise Pare Elancourt
France CHU de Nantes - Hopital Hotel Dieu Nantes Cedex 1
Germany Rheinhessen-Fachklinik Mainz, Kinder und Jugendpsychiatri Mainz
Hungary Vadaskert Alapitvany Budapest
Hungary Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza Gyula
Israel Shalvata Mental Health Center Hod Hasharon
Israel Ramat Chen - Mental Health Clinic Tel Aviv
Israel The Chaim Sheba Medical Center - The Edmond and Lily Safra Children's Hospital Tel Hashomer
Italy Scientific Institute Fondazione Stella Maris Calambrone Pisa Pisa
Italy University Federico II Of Naples Napoli
Italy Sciaf Ulss 16 Padova Padova Regione Veneto
Korea, Republic of Seoul National University Hospital Seoul
Latvia Linda Keruze's Psychiatric Center, LLC Liepaja
Latvia Children Hospilal -Gailezers Riga
Mexico ICARO Investigaciones en Medicina S.A. de C.V. Chihuahua
Mexico Instituto Nacional de Pediatria (INP) (National Institute of Pediatrics) Ciudad de Mexico Distrito Federal
Mexico Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C Culiacan De Rosales Sinaloa
Mexico Centro Investigacion Medico Biologica Y Terapia Avanzada Guadalajara Jalisco
Mexico Clinica Cemelli Guadalajara Jalisco
Mexico Roberto Zepeda Sanchez Guadalajara Jalisco
Mexico B & B Investigaciones Medicas, SC Mazatlan Sinaloa
Mexico CRI Centro Regiomontano de Investigacion SC Monterrey Nuevo Leon
Mexico BIND Investigaciones S.C San Luis Potosi
Poland Prywatne Gabinety Lekarskie Promedicus Bialystok Podlaskie
Poland Centrum Badan Klinicznych PI-House Sp. z o.o. Gdansk
Poland Przychodnia Syntonia Poradnia Zdrowia Psychicznego Kielce
Poland Spectrum Centrum Psychiatrii Specjalistyczny Gabinet Psychiatryczny Lublin
Poland Filip Rybakowski Specjalistyczna Praktyka Lekarska Poznan
Poland Specjalistyczny Szpital im. dra A. Sokolowskiego w Walbrzychu Walbrzych
Russian Federation Arkhangelsk Regional Clinical Mental Hospital Arkhangelsk
Russian Federation State Budgetary Healthcare Institution of Sverdlovsk Region ¿Sverdlovsk Regional Clinical Psychi... Ekaterinburg
Russian Federation GUZ Engels Psychiatric Hospital Engels
Russian Federation State Budgetary Healthcare Institution (SBHI) Specialized Clinical Psychiatric Hospital 1 of the ... Krasnodar
Russian Federation LLC City Neurological Center Sibneuromed Novosibirsk
Russian Federation Medicorehabilitation Research Center Phoenix Rostov-On-Don Rostov State
Russian Federation Rostov State Medical University of the Minzdravsotsrazvitiya of Russia Rostov-on-Don
Russian Federation Guz Saratov Regional Psychiatric Hospital St. Sofii Saratov
Russian Federation Saratov State Medical University Saratov
Russian Federation City Psychiatric Hospital No.3 named after I.I. Skvortsov-Stepanov St-Petersburg
Russian Federation Stavropol Region Psychiatric Hospital No.2 Stavropol Stavropol Region
Russian Federation Nebbiolo LLC Tomsk
Russian Federation Yaroslavl Regional Clinical Psychiatry Hospital Yaroslavl
Serbia Child and Adolescent Neurology and Psychiatry Clinic Belgrade
Serbia Institute of Mental Health Belgrade
Serbia University Clinical Center Kragujevac Kragujevac
Serbia Clinical Center of Vojvodina - Clinic of Psychiatry Novi Sad
Serbia Daily Hospital for Children and Adolescents Pantelej-Nis
South Africa Cape Trial Centre Bellville Cape Town
South Africa Tara Hospital Sandhurst Gauteng
Spain Hospital Universitario Fundacion Alcorcon Alcorcon Madrid
Spain Unidad de Salud Mental Infanto-Juvenil (USMI-J) Edificio de Consultas Externas. Hospital MarAtimo Torremolinos Malaga
Ukraine Ukrainian Research Institute Of Social, Forensic Psychiatry And Drug Abuse, Kiev City Psychoneuro... Kyiv
Ukraine Odessa Regional Medical Centre of Mental Health Odessa
Ukraine Maltsev Poltava Regional Clinical Psychiatric Hospital, Higher State Educational Institution Of U... Poltava
Ukraine Ternopil Regional Clinical Municipal Psycho-Neurological Hospital, Ternopil State Medical Univers... Ternopil
United States Atlanta Center for Medical Research Atlanta Georgia
United States BioBehavioral Research of Austin Austin Texas
United States Kennedy Krieger Institute Baltimore Maryland
United States American Medical Research, Inc. Chicago Illinois
United States University of Cincinnati Medical Center Cincinnati Ohio
United States University Hospital Cleveland Medical Center Division of Child and Adolescent Psychiatry Cleveland Ohio
United States Westside Medical Clinton Utah
United States Sarkis Clinical Trials Gainesville Florida
United States Sun Valley Research Center Imperial California
United States Lake Charles Clinical Trials Lake Charles Louisiana
United States Synergy Clinical Research Center Lemon Grove California
United States Woodland International Research Group Little Rock Arkansas
United States Alliance for Wellness dba Alliance for Research Long Beach California
United States Northwest Behavioral Research Center Marietta Georgia
United States Research Strategies Of Memphis, Llc Memphis Tennessee
United States North Star Medical Research, LLC Middleburg Heights Ohio
United States AMR- Baber Research, Inc. Naperville Illinois
United States Manhattan Behavioral Medicine New York New York
United States IPS Research Company Oklahoma City Oklahoma
United States Paradigm Research Professionals, LLC Oklahoma City Oklahoma
United States NRC Research Institute Orange California
United States Medical Research Group of Central Florida Orange City Florida
United States Aspen Clinical Research, LLC Orem Utah
United States Asclepes Research Center Panorama City California
United States AIM Trials, LLC Plano Texas
United States Research Across America Plano Texas
United States Princeton Medical Institute Princeton New Jersey
United States Finger Lakes Clinical Research Rochester New York
United States St. Charles Psychiatric Associates - Midwest Research Group Saint Charles Missouri
United States Millennium Psychiatric Associates, LLC Saint Louis Missouri
United States Clinical Trials of Texas, Inc. San Antonio Texas
United States AMR Conventions Research Warrenville Illinois
United States Children's National Medical Center Merge Washington District of Columbia
United States Kansas University School of Medicine-Wichita Wichita Kansas

Sponsors (2)

Lead Sponsor Collaborator
H. Lundbeck A/S Takeda

Countries where clinical trial is conducted

United States,  Bulgaria,  Canada,  Colombia,  Estonia,  France,  Germany,  Hungary,  Israel,  Italy,  Korea, Republic of,  Latvia,  Mexico,  Poland,  Russian Federation,  Serbia,  South Africa,  Spain,  Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Least square (LS) mean was estimated using a restricted maximum likelihood (REML)-based Mixed Model Repeated Measurements (MMRM) approach. Baseline (Week 4 of Phase A), Week 8 of Phase B
Secondary Change From Baseline in CDRS-R Total Score at Weeks 2, 4, and 6 of Phase B The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Baseline (Week 4 of Phase A), Weeks 2, 4, and 6 of Phase B
Secondary Change From Baseline in CDRS-R Subscores (Mood, Somatic, Subjective, and Behaviour) at Weeks 2, 4, 6, and 8 of Phase B The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Four subscores were defined based on the CDRS-R: Mood: sum of items 8, 11, 14, 15; score range 4 to 28, Somatic: sum of items 4, 5, 6, 7, 16, 17; score range 6 to 36, Subjective: sum of items 9, 10, 12, 13; score range 4 to 28, and Behaviour: sum of items 1, 2, 3; score range 3 to 21. Higher scores indicated the most severe measure of depression. Baseline (Week 4 of Phase A), Weeks 2, 4, 6, and 8 of Phase B
Secondary Percentage of Participants With CDRS-R Response CDRS-R response was defined as a =50% decrease in CDRS-R total score, calculated as: (change from baseline [Randomization])/(baseline value - 17). The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Weeks 2, 4, 6, and 8 of Phase B
Secondary Percentage of Participants With CDRS-R Remission CDRS-R remission was defined as a CDRS-R total score =28. The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Weeks 2, 4, 6, and 8 of Phase B
Secondary Change From Baseline in General Behaviour Inventory (GBI) Depression Subscale Score, Using the 10-Item Depression Subscale Assessed by Parent (PGBI-10D) and Child (CGBI-10D) at Weeks 2, 4, 6, and 8 of Phase B The GBI 10-item depression scale was developed to screen for depressive symptoms in children and adolescents. Two versions of the GBI 10-item depression scale were used, the child rated version (CGBI) and the parent rated version (PGBI). The 10 depression items were rated on a 4-point scale from 0 (never or hardly ever) to 3 (very often or almost constantly). The total score ranged from 0 to 30, with higher scores indicating greater pathology. Baseline (Week 4 of Phase A), Weeks 2, 4, 6, and 8 of Phase B
Secondary Parent Global Assessment (PGA) Score The PGA is a parent-rated variation of the CGI-I to evaluate the severity of the child's symptoms. The PGA reflects assessments of symptoms using a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Weeks 2, 4, 6, and 8 of Phase B
Secondary Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Weeks 1, 2, 3, 4, 6, and 8 of Phase B The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants). Baseline (Week 4 of Phase A), Weeks 1, 2, 3, 4, 6, and 8 of Phase B
Secondary Clinical Global Impression - Global Improvement (CGI-I) Score The CGI-I provides the clinician's impression of the participant's improvement (or worsening). The clinician assesses the participant's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Weeks 1, 2, 3, 4, 6, and 8 of Phase B
Secondary Percentage of Participants With CGI-S Remission CGI-S remission was defined as a CGI-S score of 1 or 2. The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants). Weeks 1, 2, 3, 4, 6, and 8 of Phase B
Secondary Change From Baseline in Children's Global Assessment Scale (CGAS) Score at Weeks 4 and 8 of Phase B The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally-oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The score ranges from 1 (most functionally impaired child) to 100 (the healthiest). A score greater than 70 indicates normal function. Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Secondary Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score at Weeks 4 and 8 of Phase B The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome. Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Secondary Change From Baseline in PedsQL VAS: Sad or Blue (Sadness) Score at Weeks 4 and 8 of Phase B The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome. Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Secondary Change From Baseline in PedsQL VAS: Angry Score at Weeks 4 and 8 of Phase B The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome. Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Secondary Change From Baseline in PedsQL VAS: Worry Score at Weeks 4 and 8 of Phase B The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome. Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Secondary Change From Baseline in PedsQL VAS: Tired (Fatigue) Score at Weeks 4 and 8 of Phase B The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome. Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Secondary Change From Baseline in PedsQL VAS: Pain or Hurt Score at Weeks 4 and 8 of Phase B The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome. Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Secondary Change From Baseline in PedsQL VAS Total Average Score at Weeks 4 and 8 of Phase B The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using visual analogue scales. The functionality for each domain is measured on a 10cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The total score is the average of all 6 items. A lower value represents a better outcome. Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Secondary Change From Baseline in PedsQL Emotional Distress Summary Average Score at Weeks 4 and 8 of Phase B The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The average emotional distress summary score is the mean of the anxiety, sadness, anger, and worry items. A lower value represents a better outcome. Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Secondary Change From Baseline in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Score (Items 1 to 14) at Weeks 4 and 8 of Phase B The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire, which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1 to 14 assess the degree of satisfaction experienced by participants in various areas of daily functioning, and item 15 allows subjects to summarise their experience in a global rating. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total score range of item 1 to 14 is 14 to 70, with higher scores indicating greater satisfaction. Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Secondary Change From Baseline in PQ-LES-Q Overall Evaluation Score (Item 15) at Weeks 4 and 8 of Phase B The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire, which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1 to 14 assess the degree of satisfaction experienced by participants in various areas of daily functioning, and item 15 allows subjects to summarize their experience in a global rating. Item 15 is rated on a 5-point scale from 1 (very poor) to 5 (very good). Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
See also
  Status Clinical Trial Phase
Recruiting NCT05915013 - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response Phase 1
Completed NCT04469322 - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression N/A
Recruiting NCT05415397 - Treating Immuno-metabolic Depression With Anti-inflammatory Drugs Phase 3
Recruiting NCT05988333 - Psychoeducational Intervention for Families With a Member Affected by Major Depression N/A
Completed NCT02919501 - Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder Phase 2
Completed NCT00976560 - Clinical Study to Test a New Drug to Treat Major Depression Phase 2
Recruiting NCT05518149 - A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) Phase 3
Not yet recruiting NCT06303076 - Tizanidine vs. Zolpidem in Primary Insomnia: A Randomized Trial Phase 4
Not yet recruiting NCT05901571 - Acupuncture and Escitalopram for Treating Major Depression Clinical Study N/A
Completed NCT02452892 - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) N/A
Suspended NCT02546024 - Predictors of Treatment Response in Late-onset Major Depressive Disorder N/A
Completed NCT01407575 - Buprenorphine for Treatment Resistant Depression Phase 3
Completed NCT01583400 - Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial N/A
Completed NCT01152996 - Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study Phase 3
Enrolling by invitation NCT00762866 - Psychiatric Genotype/Phenotype Project Repository
Completed NCT00384033 - Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder Phase 3
Completed NCT00369343 - Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women Phase 3
Completed NCT00366652 - Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects Phase 3
Completed NCT00316160 - Sexual Functioning Study With Antidepressants Phase 4
Completed NCT00149643 - Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence Phase 2